Q3 2024 BioXcel Therapeutics Inc Earnings Call Transcript
Key Points
- BioXcel Therapeutics Inc (BTAI) announced important milestones with two pivotal Phase 3 trials for BXCL501, targeting agitation associated with bipolar disorder, schizophrenia, and Alzheimer's dementia.
- The SERENITY at home trial for BXCL501 represents a near-term growth opportunity and is the company's immediate focus area.
- The company received a Department of Defense grant to fund a Phase 2a study of BXCL501 for acute stress disorder, highlighting external validation of its therapeutic potential.
- Research and development expenses significantly decreased from $19.6 million in Q3 2023 to $5.1 million in Q3 2024, reflecting cost management and reprioritization efforts.
- BioXcel Therapeutics Inc (BTAI) reported an 89% increase in net revenue for the nine months ended September 30, 2024, compared to the same period in 2023, indicating rising utilization of IGALMI.
- Net revenue for IGALMI decreased to $214,000 in Q3 2024 from $341,000 in Q3 2023, primarily due to the timing of reorders from existing customers.
- The company reported a net loss of $13.7 million for Q3 2024, although this was an improvement from a $50.5 million loss in Q3 2023.
- Cost of goods sold increased significantly to $1.2 million in Q3 2024 from $512,000 in Q3 2023, due to higher non-cash charges for reserves for excess or obsolete inventory.
- BioXcel Therapeutics Inc (BTAI) is working to strengthen its balance sheet and is evaluating strategic financing alternatives, indicating potential financial challenges.
- The TRANQUILITY In-Care trial protocol had to be adjusted following FDA feedback, which could impact timelines and resource allocation.
Good morning, and welcome to the BioXcel Therapeutics Third-Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. (Operator Instructions) After the formal remarks, there will be a question-and-answer session. (Operator Instructions)
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
Risk factors that could affect future results are detailed in the company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2024, which can be found at www.bioxceltherapeutics.com or on www.sec.gov and which will be updated in its quarterly report on Form 10-Q for the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
